4572-03-6Relevant articles and documents
Structural optimizations and bioevaluation of N-substituted acridone derivatives as strong topoisomerase II inhibitors
Li, Xun,Li, Zhi-Ying,Song, Yu-Liang,Xu, Guang-Sen
, (2022/01/14)
Previously, an array of N-substituted acridone derivatives have been reported as potent topoisomerase II (topo II) inhibitors, and preliminary structure–activity relationship (SAR) outcomes revealed that the linker between 1-NH and N-methyl piperazine motif of the tricyclic acridone scaffold significantly affected their anti-proliferative potencies. To further explore the SARs of acridone-derived topo II inhibitors, a wider range of novel acridone derivatives were herein synthesized via two rounds of structural optimizations on two validated hits, E17 and E24. Initially, the linker length was optimized, and then influences of N-methyl piperazinyl moiety and disposition of three N atoms on the bioactivity were investigated. As a result, a newly developed topo II inhibitor 6 h was found to be more potent than E17 and E24, thereby serving as a tool compound for the follow-up mechanistic study. Compound 6 h functioned as a strong topo IIα/β inhibitor, caused obvious DNA damage, and induced apoptosis by triggering the loss of mitochondrial membrane potential (Δψm). Further molecular docking and MD study illustrated the favorable interactions of 6 h with both topo IIα and topo IIβ subtypes.
PROCESS FOR THE MANUFACTURE OF 3-PIPERAZIN-1-YL-PROPYLAMINE DERIVATIVES
-
Page/Page column 8, (2017/09/15)
The invention relates to the manufacture of a compound of formula (I), wherein R1 is defined as in the description and in the claims.
Synthesis and antitumor activity of 5-bromo-7-azaindolin-2-one derivatives containing a 2,4-dimethyl-1H-pyrrole-3-carboxamide moiety
Zhang, Jun,Shen, Weiyi,Li, Xiaoning,Chai, Yun,Li, Senjun,Lv, Kai,Guo, Huiyuan,Liu, Mingliang
, (2016/12/30)
We report herein the design and synthesis of a series of novel 5-bromo-7-azaindolin-2-one derivatives containing a 2,4-dimethyl-1H-pyrrole-3-carboxamide moiety. These newly synthesized derivatives were evaluated for in vitro activity against selected cancer cell lines by MTT assay. Results revealed that some compounds exhibit broad-spectrum antitumor potency, and the most active compound 23p (IC50: 2.357-3.012 μM) was found more potent than Sunitinib (IC50: 31.594-49.036 μM) against HepG2, A549 and Skov-3, respectively.